---
import BaseLayout from '../layouts/BaseLayout.astro';
import { Icon } from 'astro-icon/components';
---

<BaseLayout title="Development - Path to Clinic" description="Sarkome's strategic development roadmap from in silico validation to clinical proof of concept.">
  <Fragment slot="head">
    <link href="https://fonts.googleapis.com" rel="preconnect"/>
    <link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&display=swap" rel="stylesheet"/>
  </Fragment>

  <!-- Fixed Background Layer -->
  <div class="fixed inset-0 z-0 pointer-events-none bg-ref-bg-light dark:bg-ref-bg-dark transition-colors duration-300">
      <div class="absolute inset-0 bg-[linear-gradient(to_right,#80808012_1px,transparent_1px),linear-gradient(to_bottom,#80808012_1px,transparent_1px)] bg-[size:24px_24px]"></div>
      <div class="absolute left-0 right-0 top-0 -z-10 m-auto h-[500px] w-[500px] rounded-full bg-purple-500/20 opacity-50 blur-[100px]"></div>
  </div>

  <!-- Scrollable Content Layer -->
  <div class="relative z-10 text-slate-800 dark:text-slate-200 font-sans">
    
    <!-- Header Section -->
    <header class="relative pt-6 pb-16 w-full">
        <div class="max-w-[90%] mx-auto px-4 sm:px-6 lg:px-8 text-center">
            <h1 class="text-4xl md:text-6xl font-extrabold text-slate-900 dark:text-white tracking-tight mb-6 leading-tight">
                Development <br class="hidden md:block"/>
                <span class="text-transparent bg-clip-text bg-gradient-to-r from-ref-primary to-indigo-600 dark:from-purple-400 dark:to-indigo-400">
                    Roadmap
                </span>
            </h1>
            <p class="max-w-3xl mx-auto text-lg md:text-xl text-slate-600 dark:text-slate-400 leading-relaxed">
                A rigorous, milestone-driven path from discovery to clinical entry, structured in investable tranches.
            </p>
        </div>
    </header>

    <main class="max-w-[85%] mx-auto px-4 sm:px-6 lg:px-8 pb-24 space-y-16">
        
        <!-- Current Status -->
        <section class="text-center">
             <div class="inline-flex items-center gap-3 px-6 py-3 bg-white dark:bg-slate-800 rounded-full shadow-lg border border-purple-100 dark:border-purple-900/50">
                <span class="relative flex h-3 w-3">
                  <span class="animate-ping absolute inline-flex h-full w-full rounded-full bg-purple-400 opacity-75"></span>
                  <span class="relative inline-flex rounded-full h-3 w-3 bg-purple-500"></span>
                </span>
                <span class="font-bold text-slate-800 dark:text-white">Current Phase:</span>
                <span class="font-medium text-purple-600 dark:text-purple-400">Phase 1 — In Silico Validation</span>
            </div>
        </section>

        <!-- Five-Phase Roadmap -->
        <section class="space-y-8">
            <div class="text-center mb-12">
                <h2 class="text-2xl font-bold text-slate-900 dark:text-white mb-2">Strategic Execution Timeline (2026–2031)</h2>
                <p class="text-slate-600 dark:text-slate-400">Five investable phases with clear technical milestones and go/no-go decision points.</p>
            </div>

            <!-- Phase 1 -->
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border-l-4 border-purple-500">
                <div class="flex items-start gap-4 mb-6">
                    <div class="flex-shrink-0 w-12 h-12 bg-purple-100 dark:bg-purple-900/30 text-purple-600 rounded-lg flex items-center justify-center font-bold text-lg">1</div>
                    <div class="flex-1">
                        <h3 class="text-2xl font-bold text-slate-900 dark:text-white">In Silico Validation & Hit Generation</h3>
                        <p class="text-slate-500 dark:text-slate-400 font-medium">Months 0–9 | <span class="text-purple-600 dark:text-purple-400">Milestone: Computationally Validated Hit List</span></p>
                    </div>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                    Identify chemical matter (binders) for the ASPSCR1-TFE3 fusion using structural biology and computational design.
                </p>
                <div class="grid md:grid-cols-3 gap-4">
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">1.1 Target Modeling</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Generate conformational ensembles of ASPSCR1-TFE3 using AlphaFold 3 + MD. Map interface hotspots.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">1.2 Virtual Screening</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">DiffDock campaigns against hotspots using fragment binders and E3 ligase ligands.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">1.3 Ternary Design</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Design PROTACs linking hits to VHL/CRBN E3 ligases using DeepTernary.</p>
                    </div>
                </div>
                <div class="mt-4 p-4 bg-purple-50 dark:bg-purple-900/20 rounded-lg border border-purple-100 dark:border-purple-800">
                    <p class="text-sm font-semibold text-purple-900 dark:text-purple-200"><strong>Deliverable:</strong> Prioritized list of 50–100 PROTAC designs ready for synthesis.</p>
                </div>
            </div>

            <!-- Phase 2 -->
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border-l-4 border-blue-500">
                <div class="flex items-start gap-4 mb-6">
                    <div class="flex-shrink-0 w-12 h-12 bg-blue-100 dark:bg-blue-900/30 text-blue-600 rounded-lg flex items-center justify-center font-bold text-lg">2</div>
                    <div class="flex-1">
                        <h3 class="text-2xl font-bold text-slate-900 dark:text-white">Biological Proof of Concept</h3>
                        <p class="text-slate-500 dark:text-slate-400 font-medium">Months 10–18 | <span class="text-blue-600 dark:text-blue-400">Milestone: Lead Declaration (Series A Trigger)</span></p>
                    </div>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                    Demonstrate selective degradation of ASPSCR1-TFE3 in ASPS cells and validate cellular phenotype.
                </p>
                <div class="grid md:grid-cols-2 gap-4 mb-4">
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">2.1 Synthesis</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Contract synthesis of top 50 designs (~$3k–$5k per compound).</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">2.2 Cloud Lab Screening</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">HiBiT degradation assays in ASPS-1 cells. Establish DC₅₀ and Dmax metrics.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">2.3 Selectivity</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Counter-screen vs. wild-type TFE3 and VCP to ensure fusion-specific degradation.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">2.4 Phenotypic Screen</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Confirm cell death (CellTiter-Glo) and target engagement via qPCR/Western Blot.</p>
                    </div>
                </div>
                <div class="p-4 bg-blue-50 dark:bg-blue-900/20 rounded-lg border border-blue-100 dark:border-blue-800">
                    <p class="text-sm font-semibold text-blue-900 dark:text-blue-200"><strong>Deliverable:</strong> 1–2 Lead Series with DC₅₀ &lt; 100 nM and &gt;70% degradation depth.</p>
                </div>
            </div>

            <!-- Phase 3 -->
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border-l-4 border-indigo-500">
                <div class="flex items-start gap-4 mb-6">
                    <div class="flex-shrink-0 w-12 h-12 bg-indigo-100 dark:bg-indigo-900/30 text-indigo-600 rounded-lg flex items-center justify-center font-bold text-lg">3</div>
                    <div class="flex-1">
                        <h3 class="text-2xl font-bold text-slate-900 dark:text-white">Lead Optimization & In Vivo Efficacy</h3>
                        <p class="text-slate-500 dark:text-slate-400 font-medium">Months 19–30 | <span class="text-indigo-600 dark:text-indigo-400">Milestone: Preclinical Candidate Nomination</span></p>
                    </div>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                    Develop drug-like properties and validate efficacy in in vivo tumor models.
                </p>
                <div class="grid md:grid-cols-3 gap-4 mb-4">
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">3.1 MedChem</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Optimize linkers for solubility, permeability, and metabolic stability (ADME profiling).</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">3.2 PK/PD</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Pharmacokinetic studies in mice to determine half-life and systemic exposure.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">3.3 In Vivo Efficacy</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Test in ASPS patient-derived xenograft (PDX) models. Demonstrate tumor regression.</p>
                    </div>
                </div>
                <div class="p-4 bg-indigo-50 dark:bg-indigo-900/20 rounded-lg border border-indigo-100 dark:border-indigo-800">
                    <p class="text-sm font-semibold text-indigo-900 dark:text-indigo-200"><strong>Deliverable:</strong> Preclinical Candidate (PCC) with validated in vivo efficacy and acceptable safety profile.</p>
                </div>
            </div>

            <!-- Phase 4 -->
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border-l-4 border-emerald-500">
                <div class="flex items-start gap-4 mb-6">
                    <div class="flex-shrink-0 w-12 h-12 bg-emerald-100 dark:bg-emerald-900/30 text-emerald-600 rounded-lg flex items-center justify-center font-bold text-lg">4</div>
                    <div class="flex-1">
                        <h3 class="text-2xl font-bold text-slate-900 dark:text-white">IND-Enabling Studies</h3>
                        <p class="text-slate-500 dark:text-slate-400 font-medium">Months 31–42 | <span class="text-emerald-600 dark:text-emerald-400">Milestone: Clinical Entry (FDA Safe to Proceed)</span></p>
                    </div>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                    Regulatory clearance package for human trials.
                </p>
                <div class="grid md:grid-cols-3 gap-4 mb-4">
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">4.1 GLP Toxicology</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Pivotal tox studies in rodent + non-rodent species. Establish NOAEL (No Observed Adverse Effect Level).</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">4.2 CMC</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Process development for GMP manufacturing of drug substance and product.</p>
                    </div>
                    <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700">
                        <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">4.3 Regulatory</h4>
                        <p class="text-sm text-slate-600 dark:text-slate-400">Pre-IND meeting with FDA. Submit Investigational New Drug (IND) application.</p>
                    </div>
                </div>
                <div class="p-4 bg-emerald-50 dark:bg-emerald-900/20 rounded-lg border border-emerald-100 dark:border-emerald-800">
                    <p class="text-sm font-semibold text-emerald-900 dark:text-emerald-200"><strong>Deliverable:</strong> FDA "Safe to Proceed" letter; regulatory clearance for Phase 1 initiation.</p>
                </div>
            </div>

            <!-- Phase 5 -->
            <div class="bg-white dark:bg-slate-800 rounded-2xl p-8 shadow-lg border-l-4 border-pink-500">
                <div class="flex items-start gap-4 mb-6">
                    <div class="flex-shrink-0 w-12 h-12 bg-pink-100 dark:bg-pink-900/30 text-pink-600 rounded-lg flex items-center justify-center font-bold text-lg">5</div>
                    <div class="flex-1">
                        <h3 class="text-2xl font-bold text-slate-900 dark:text-white">Clinical Proof of Concept & Exit</h3>
                        <p class="text-slate-500 dark:text-slate-400 font-medium">Year 4+ | <span class="text-pink-600 dark:text-pink-400">Milestone: Phase 1 Data Readout & M&A/IPO</span></p>
                    </div>
                </div>
                <p class="text-slate-600 dark:text-slate-300 mb-4 leading-relaxed">
                    Initiate clinical trials and prepare for strategic exit.
                </p>
                <div class="bg-slate-50 dark:bg-slate-900 p-4 rounded-lg border border-slate-200 dark:border-slate-700 mb-4">
                    <h4 class="font-bold text-slate-800 dark:text-slate-200 mb-2 text-sm uppercase tracking-wide">Phase 1/2 Basket Trial</h4>
                    <p class="text-sm text-slate-600 dark:text-slate-400">Enroll patients with TFE3-rearranged malignancies (ASPS + tRCC). Establish safety, tolerability, and preliminary efficacy signals in humans.</p>
                </div>
                <div class="p-4 bg-pink-50 dark:bg-pink-900/20 rounded-lg border border-pink-100 dark:border-pink-800">
                    <p class="text-sm font-semibold text-pink-900 dark:text-pink-200"><strong>Exit Strategy:</strong> Phase 1 safety + efficacy data typically triggers interest from large pharma partners for acquisition or co-development, or positions company for IPO.</p>
                </div>
            </div>
        </section>

        <!-- Regulatory & Competitive Strategy -->
        <section class="bg-ref-surface-light dark:bg-ref-surface-dark rounded-2xl p-8 md:p-12 shadow-xl border border-slate-200 dark:border-slate-700">
            <div class="flex items-center gap-3 mb-6">
                <div class="p-2 bg-blue-100 dark:bg-blue-900/50 rounded-lg text-blue-600">
                    <Icon name="mdi:file-document-check" class="w-6 h-6" />
                </div>
                <h2 class="text-2xl font-bold text-slate-900 dark:text-white">Regulatory & Competitive Strategy</h2>
            </div>
            <div class="grid md:grid-cols-3 gap-8">
                <div>
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-2">Orphan Drug Designation (ODD)</h3>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed text-sm">
                        Early filing for ODD for Alveolar Soft Part Sarcoma provides 7 years of market exclusivity, tax credits, and FDA fee waivers—reducing commercial risk.
                    </p>
                </div>
                <div>
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-2">Basket Trial Design</h3>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed text-sm">
                        Clinical trials targeting all TFE3-rearranged malignancies (ASPS + translocation-associated RCC) expands addressable market and accelerates enrollment.
                    </p>
                </div>
                <div>
                    <h3 class="text-lg font-semibold text-slate-800 dark:text-slate-200 mb-2">IP Fortress</h3>
                    <p class="text-slate-600 dark:text-slate-300 leading-relaxed text-sm">
                        Parallel patent filings throughout development ensure composition of matter, methods of use, and formulation claims covering the therapeutic and manufacturing innovations.
                    </p>
                </div>
            </div>
        </section>

    </main>
  </div>
</BaseLayout>
